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Abstract: Neuropathic pain is originated from different alterations of the nervous 
system. The difficulty of treatment strongly impairs quality of life of affected 
people. It is associated with severe, chronic sensory disturbances characterized by 
spontaneous pain, increased responsiveness to painful stimuli and pain perceived in 
response to normally non-noxious stimuli. The underlying mechanisms are complex 
and involve both peripheral and central nervous components.The noradrenergic 
system plays a pivotal role in the control of pain since its widespread distribution in 
the “pain matrix” representing a valuable therapeutic target. This review focused on 
the α2 adrenoceptor subtype modulation as strategy for neuropathic pain relief. 
Drugs acting as direct α2 adrenoceptor agonists (clonidine and dexmedetomidine) 
were analyzed as well as the indirect α2 adrenoceptor modulators. The overview included 
norepinephrine reuptake inhibitors (reboxetine, maprotiline), serotonin/norepinephrine reuptake 
inhibitors (venlafaxine, milnacipran, amitriptyline, duloxetine, bicifadine) and the compounds 
characterized by a double pharmacodynamic mechanism combining the norepinephrine reuptake 
inhibition and the µ opioid agonist profile (tramadol and tapentadol). A summary of recent compounds 
was illustrated. 
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1. INTRODUCTION 
1.1. Neuropathic Pain and Noradrenergic System 
 Neuropathic pain (NP) is estimated to afflict millions of 
people worldwide [1-3]. Many common diseases, injuries, 
chemotherapy drugs and interventions cause NP by 
producing lesions in somatosensory pathways in the 
peripheral or central nervous system [4]. An exaggerated 
response to non noxious stimuli (referred as allodynia) and 
an excessive response to noxious or painful stimuli (referred 
as hyperalgesia) are the common clinical symptoms [5]. The 
pathological aspects of NP involve a maladaptive response 
of the nervous system characterized by peripheral and central 
sensitization as well as by spinal disinhibition [5]. The 
impairment of the spinal control of pain is strictly related to 
the dysregulation of the descending pain modulatory system. 
The descending pathways originate in the midbrain 
(periaqueductal gray; PAG) and brainstem (rostroventromedial  
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medulla; RVM) and project to the spinal cord dorsal horn, 
powerfully influencing the modulation of nociceptive 
information transmitted from the periphery to the brain. The 
prominent role of this system in reducing nociception has 
been recognized by Reynolds [6] and Fields and Basbaum 
[7].  
 More recently, the role of descending projections in pain 
facilitation and in the generation of hyperalgesic states has 
received increased attention. The descending modulatory 
system recruits norepinephrine (NE) and serotonin (5-HT) as 
its main transmitters. The role of NE appears to be 
predominantly inhibitory, while the role of 5-HT appears to 
be bidirectional, mediating inhibitory as well as excitatory 
effects [8]. The increased activity of the descending 
noradrenergic system and high extracellular levels of spinal 
NE has been linked to antinociceptive/antiallodynic/ 
antihyperalgesic effects in acute pain and NP. In the brain, 
noradrenergic cell groups are classified as A1-A7 [9]. The 
A1 cell group is located at the level of the area postrema, A2 
is distributed throughout the dorsal vagal complex, A3 is in 
the medullary reticular formation, and A4 surrounds the 
fourth ventricle. The A5 cell group is in the ventrolateral 
pons, A6 (locus coeruleus) is dorsally in the pons and A7 is 
 
L. Di Cesare Mannelli
2     Mini-Reviews in Medicinal Chemistry, 2016, Vol. 16, No. 0 Mannelli et al. 
in the lateral part of the pons, close to the lateral lemniscus. 
The main ascending noradrenergic projection pathways in 
the central nervous system are the dorsal and ventral bundles 
and the periventricular bundle [10]. Additionally, cell groups 
A5-A7 have significant descending noradrenergic projections to 
the spinal cord [11, 12]. Moreover, the noradrenergic locus 
coeruleus (LC) is the main nucleus in the pons involved in 
pain processing, and based on classical studies of acute pain 
modulation, it also mediates the inhibition of pain. LC 
neurons are the crossroads of an elaborate network of 
ascending and descending projections [13]. Descending 
inhibitory noradrenergic fibers reach the substantia gelatinosa 
reducing pain at the spinal level [14, 15]. Furthermore, 
ascending inputs from the LC to cortical areas, such as the 
prefrontal cortex (PFC), modulate the cortico-thalamic loop 
that processes the affective component of pain [16].  
 NE effects are mediated by adrenergic receptors (ARs) 
divided into two main categories, α and β. ARs are G 
protein-coupled membrane receptors divided into 9 subtypes 
encoded by different genes: three α1 ARs, three α2 ARs and 
three β1 ARs [17-20]. α1 subtypes are collectively 
characterized by their positive coupling via Gq to voltage-
gated Ca2+ channels and phospholipase C (PLC), activation 
of which mobilises intracellular pools of calcium. The three 
classes of β ARs stimulate the activity of adenylyl cyclase by 
Gs leading to an increase of neuronal excitability [21]. On 
the contrary, the three α2 AR subtypes (α2A, α2B and α2C) 
couple with Gi/o and are related to adenylyl cyclase 
inhibition, K+ current enhancement and to reduction of Ca2+ 
currents [22]. α2 ARs are involved in different physiological 
functions and all the three subtypes have been identified as 
potential contributors to nociceptive modulation being 
located in key nodes of the nociceptive system [23-25]. 
Pharmacological or genetic manipulations demonstrated that 
α2 ARs can alter nocifensive behaviours and/or neuronal 
activity [26-31]. α2 AR stimulation induce analgesia by 
directly acting on the spinal cord [32-37] producing both 
post-synaptic hyperpolarization [38] and presynaptic 
inhibition of excitatory transmission [39]. In general, 
activation of postsynaptic α2 ARs produces hyperpolarization 
by the activation of G protein-coupled inwardly-rectifying 
potassium channels via Gi/o-proteins. Presynaptic α2 ARs 
reduce neurotransmitter release by inhibiting calcium influx 
[40]. In the noradrenergic neurons of the LC, α2 ARs act as 
autoreceptors to reduce local norepinephrine release [41] and 
also induce postsynaptic hyperpolarization [42]. Recently, 
Funai et al. [43], suggest that systemic α2 AR stimulation 
may facilitate inhibitory synaptic responses in the superficial 
dorsal horn to produce analgesia mediated by activation of 
the pontospinal noradrenergic inhibitory system.  
 The present review intends to be a contribution to the 
comprehension of the α2 AR role in neuropathic states 
focusing on the pharmacological modulation. 
1.2. Direct α2 AR Modulation 
1.2.1. Effect of α2 AR agonists 
 There is considerable preclinical and clinical evidence 
that α2 AR agonists elicit analgesia against a diversity of 
painful states, including NP.  
 Clonidine showed anti-hyperalgesic activity after 
intrathecal (i.t.) administration in patients with NP [44, 45]. 
Clonidine inhibits nociceptive impulse by α2 ARs in the 
dorsal horn of the spinal cord promoting inhibitory 
interactions with the pre and post synaptic primary afferent 
nociceptive projections [46] and the inhibition of substance P 
release [47]. The α2 selective antagonist yohimbine reversed 
clonidine-induced analgesia [46]. Clonidine may be useful 
for patients tolerant, non-responsive or allergic to morphine 
or other opioids. Indeed, clonidine is approved by the United 
States Food and Drug Administration (FDA) for epidural 
administration in the treatment of neuropathic cancer pain 
and, together with drugs that enhance NE concentrations in 
the spinal cord (amitriptyline and duloxetine), it is 
considered a first-line treatment for NP [4] The efficacy of 
clonidine to relieve NP was tested by Feng [48] in a rat 
model of partial sciatic nerve ligation-induced 
hypersensitivity. Fourteen days after surgery 5, 10 and 20 µg 
clonidine, i.t. injected, was able to attenuate mechanical and 
thermal hyperalgesia in a dose-dependent manner. The 
attenuation of pain paralleled with microglia and astrocyte 
inhibition [48]. The inhibitory effect of clonidine on glia 
cells was explained by the authors as result of decreased 
proinflammatory cytokines (IL-1β and IL-6) [48].  
 Poree [49] investigated the analgesic potency and site of 
action of systemic (intraperitoneally; i.p.) dexmedetomidine 
in naive and neuropathic rats (L5 and L6 spinal nerve 
ligation model; SNL). Neuropathic animals responded to 
smaller doses of dexmedetomidine in comparison to naive 
rats. Atipamezole, a selective α2 AR antagonist, blocked 
dexmedetomidine pain reliever effect both in NP and control 
animals. On the contrary, a peripherally restricted α2 AR 
antagonist blocked the anti-hyperalgesic actions of 
dexmedetomidine in neuropathic rats only. A nerve injury-
dependent shift of the α2 analgesic site of action outside the 
blood-brain barrier was hypothesized and a peripheral 
restricted α2 AR agonist was suggested for the management 
of NP [49]. As regards the α2 AR subtype involved in pain 
modulation, Robinson et al. [50] showed the loss of 
clonidine analgesic effect in α2A knockdown animals. 
Moreover, in mice lacking the α2A AR gene the data was 
confirmed for both the analgesic [51] (increase of normal 
pain threshold) and anti-hyperalgesic [34] (increase of 
altered pain threshold) efficacy of dexmedetomidine i.p. or 
subcutaneously (s.c.) administered. This selectivity was not 
confirmed when α2 AR agonists were intraplantarly injected 
in rat underwent SNL [52]. The anti-hypersensitivity effect 
of intraplantar dexmedetomidine was reversed by ipsilateral 
(but not contralateral) intraplantar injection of yohimbine (a 
non selective α2 adrenoceptor antagonist), as well as by 
intraplantar injections of BRL 44408, ARC 239, and JP 
1302, α2A, α2B, and α2C AR antagonist, respectively [52].  
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1.3. Indirect α2 AR Modulation 
1.3.1. Effect of Norepinephrine Reuptake Inhibitors 
 Clinical studies suggest that the efficacy of 5-HT and NE 
reuptake inhibitors (SNRIs) for neuropathic pain is greater 
than that of selective 5-HT reuptake inhibitors (SSRIs) [53]. 
Moreover, Nakjima et al. [53] demonstrated that an increase 
in NE in the spinal cord plays an important role in the 
antihyperalgesic effects of not only SNRIs but also SSRIs. 
Recent researches in this area have explored the use of 
purely noradrenergic reuptake inhibitors as analgesic 
treatment. Preclinical research suggests that noradrenergic 
antidepressants may have antinociceptive effects comparable 
to mixed tricyclic antidepressants [54].  
 The recent introduction of reboxetine, a selective NE 
reuptake inhibitor, contributed to increase the interest in the 
catecholamine pathway for NP treatment. Its comparatively 
low affinity for muscarinic acetylcholine receptors causes 
less dry mouth, constipation, and other side effects 
characteristic of tricyclic antidepressants. Moreover, nausea, 
diarrhea, and hypotension appear to be less common since 
reboxetine does not block α1 AR or the 5-HT transporter. 
Reboxetine is non-sedating and widespread used in 
neuropathic, musculoskeletal pain and in fibromyalgia [55]. 
In rats underwent to tibial nerve transection, reboxetine i.t. or 
systemically injected reduced neuropathic pain; the 
antiallodynic effect was blocked by prior administration of 
yohimbine but not by prazosin (α1 AR antagonist) or 
propranolol (β AR antagonist) [56]. As regards fibromyalgia, 
a disorder characterized by pain, muscle tenderness, fatigue 
and sleep disturbance, [57, 58] the active reboxetine 
enantiomer esreboxetine induced clinical benefit with the 
least risk of drug exposure [59]. 
 Maprotiline was compared with amitriptyline in the 
treatment of postherpetic neuralgia evaluating the relief of 
steady pain, brief pain and pain dues to tactile stimulation. 
Maprotiline relieved pain but was not as effective as 
amitriptyline conversely it was effective when amitriptyline 
failed [60]. The relationship between the maprotiline pain 
reliever effect and α2 AR activation was demonstrated for 
acute pain [61].  
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1.3.2. Effect of Serotonin/Norepinephrine Reuptake 
Inhibitors 
 The higher efficacy of SNRI in comparison to SSRI 
emerges from a preclinical study performed in neuropathic 
rat. The SNRI Milnacipran, produced a dose-dependent (3 – 
30 mg/kg; i.p.) antihyperalgesic effect. The effect was 
reversed by i.t. injection of the α2 AR antagonist idazoxan 
(30µg), but not by various 5-HT receptor antagonists. 
Paroxetine produced an antihyperalgesic effect only at the 
highest dose tested and it was reversed by intrathecal 
injection of both idazoxan and ondansetron (30µg), a 5-HT3 
receptor antagonist [53]. Milnacipran is licensed for the 
treatment of fibromyalgia in some countries. Efficacy seems 
to be similar to that induced by duloxetine and pregabalin 
[62] even if a recent review of literature data reports that 
milnacipram provides moderate pain relief in a minority of 
treated patients increasing adverse events and adverse 
withdrawals [63]. 
 Venlafaxine is a 5-HT/NE reuptake inhibitor that in 
comparison with other dual reuptake inhibitors such as 
duloxetine has weak affinity for 5-HT and NE transporters 
[64] and belongs to newer antidepressant drugs [65]. Its 
antinociceptive effect has been demonstrated in different 
pain models as neurogenic pain, diabetic neuropathy and 
fibromyalgia [66-69]. Venlafaxine does not induce the 
classical side effects of tricyclic antidepressants becoming a 
promising pharmacological approach for NP treatment. The 
α2 AR role in the pain reliever effect of venlafaxine was 
clarified by Hajhashemi [70] in a rat model of peripheral 
neuropathy (chronic constriction injury; CCI). Acute 
administration of venlafaxine on days 7, 14 and 21 after 
surgery was not able to reduce tactile and cold 
hypersensitivity, on the contrary repeated administrations of 
the drug (starting the first day after trauma) significantly 
prevented heat hyperalgesia and tactile hypersensitivity. 
Yohimbine reversed venlafaxine effect on heat hyperalgesia 
but not on mechanical allodynia [70]. Venlafaxine inhibits 
LC electrical activity through α2 AR [71].  
 A study performed by Benbouzid [72] showed that the 
tryciclic antidepressants that act by blocking NE and 5-HT 
reuptake requires a chronic treatment to alleviate NP as 
observed against depression. The authors used a murine NP 
model induced by the unilateral insertion of a polyethylene 
cuff around the main branch of the sciatic nerve to produce a 
long lasting ipsilateral allodynia. Amitryptiline (5 mg/kg; 
lower than that used as antidepressant) was administered i.p. 
bid for 3 weeks starting 15 days after surgical procedure. 
Ten days after treatment, amitriptyline was able to suppress 
the cuff-induced allodynia measured by Von Frey test. On 
the contrary, the acute treatment was ineffective [72]. 
Zychowska [73] demonstrated that amitriptyline in CCI-
exposed rats attenuated only mechanical allodynia with no 
significative effects on thermal hyperalgesia. These results 
are consistent with Berrocoso [74] that observed higher 
efficacy of acute amitriptyline (10 mg/kg) against 
mechanical allodynia in comparision to cold allodynia in a 
rat model of NP.  
 
4     Mini-Reviews in Medicinal Chemistry, 2016, Vol. 16, No. 0 Mannelli et al. 
 The anti hyperalgesic effect of duloxetine was 
investigated in rats which underwent to CCI with particular 
attention to the LC activity [75]. CCI did not modify the 
basal tonic activity in the LC although was able to alter the 
animals response to noxious stimuli. Under normal 
conditions, noxious stimulation evoked an early LC neuron 
response, dependent and comparable with gabapentin [77]. 
Bicifadine efficacy was also confirmed in the streptozotocine 
model of diabetic NP, 6 min after administration the paw 
withdrawal was significantly higher in comparison to 
vehicle-treated diabetic rats and was not different from 
nondiabetic rat response [77]. Corresponding to the 
activation of myelinated A fibers, which is followed by an 
inhibitory period and a subsequent late capsaicin-sensitive 
response, consistent with the activation of unmyelinated C 
fibers [76]. CCI provoked an enhanced excitatory early 
response in the animals and the loss of the late response. The 
continuous administration (by osmotic pump s.c.) over 7 
days of desipramine (10 mg/kg/day) or duloxetine (5 mg/kg/ 
day) decreased the excitatory firing rate of the early response 
in the CCI group [75].  
 Bicifadine inhibits monoamine neurotransmitter uptake 
in vitro (recombinant human monoamine transporters) with a 
relative potency of NE > 5-HT > dopamine (DA) (≈1:2:17). 
This in vitro profile is supported by microdialysis studies in 
freely moving rats, where bicifadine (20 mg/kg i.p.) 
increased extrasynaptic NE and 5-HT concentrations in the 
prefrontal cortex, NE levels in the locus coeruleus, and DA 
levels in the striatum [77]. Although NE levels increased 
more rapidly that 5-HT, both neurotransmitters reached 
similar maxima 40 min after bicifadine administration [77]. 
However, additional aspects of the molecular pharmacology 
of bicifadine may contribute to the antinociceptive profile. 
Bicifadine is a α2 AR agonist and a full 5-HT1A receptor 
agonist [78, 79]. The molecule was effective in reducing 
mechanical and thermal hyperalgesia and mechanical allodynia 
in the rat NP model of SNL. The effect was dose-dependent.  
1.3.3. Effect of µ Agonist/Norepinephrine Reuptake 
Inhibitors 
 Tramadol is a synthetic opioid of the aminocyclohexanol 
group and is globally used for the management of moderate 
and severe pain, including post-operative pain, cancer pain 
and NP [4, 80, 81]. The pharmacodynamic characteristic of 
tramadol is a dual analgesic mechanism of action, it is active 
as a µ opioid receptor agonist and as inhibitor of 5-HT and 
NE reuptake [81-85]. The relevance of α2 ARs in NP was 
highlighted injecting tramadol i.p. in neuropathic rats (partial 
spinal nerve ligation; PSNL) [86]. Tramadol acutely reduced 
mechanical allodynia, the effect was blocked by naloxone. 
Repeated administrations showed preventive and alleviative 
effects on the mechanical allodynia that was diminished by 
yohimbine, but not naloxone. Furthermore, tramadol (as well 
as amitriptyline) inhibited the nerve ligation-induced 
activation of spinal astrocytes, which was reduced by 
yohimbine. Tramadol and amitriptyline were ineffective 
against PSNL-induced microglia activation [86].  
 The analgesic effect of tramadol on NP is considered to 
be at least partly due to its interaction with presynaptic and 
postsynaptic α2 ARs located on the central terminals of 
primary nociceptive afferents and on the spinal dorsal horn 
neurons, respectively [25, 87, 88]. The pain reliever potency 
of tramadol is higher in NP than in acute pain, [89] probably 
because the activity of presynaptic and postsynaptic α2 AR is 
increased in neuropathic conditions [90].  
 Likewise tramadol, tapentadol is a dual action molecule, 
µ opioid agonist and NE reuptake inhibitor, approved for the 
management of moderate and severe pain. In contrast to 
morphine, tapentadol elevates NE levels in the ventral rat 
hippocampus [91]. Moreover, the lack of significant 
serotonergic effects clearly differentiates tapentadol from the 
‘atypical opioid’ tramadol, which produced significant 
hippocampal increases of NE as well as 5-HT [92]. 
Tapendadol double mechanism of action is particularly 
advantageous because opioids are highly efficacious against 
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acute pain whereas noradrenergic drugs are particularly 
useful in chronic NP conditions [93-95]. Moreover the two 
mechanisms interact with each other because the opioid 
component activates the descending inhibitory pathway at 
the supraspinal level (PAG and RVM) that leads to increased 
NE release in the dorsal horn reducing the nociceptive 
transmission from the primary afferents to spinal second 
order neurons [96, 97]. The different contribution of 
tapentadol opioid and noradrenergic mechanisms was 
evaluated in a rat model of nociceptive and NP by Schroder 
[98]. The antinociceptive and antihyperalgesic effect of 
tapentadol was tested in naive rats, using the tail flick test, 
and in SNL rats, using the Von Frey test. Its effects were 
antagonized by naloxone, yohimbine and ritanserin (µ, α2 
and 5-HT2A receptor antagonist, respectively). Intravenously 
administration of tapentadol induced antinociceptive and 
antihyperalgesic effect in naive and neuropathic rats with 
median effective dose (ED50) values of 3.3 mg/kg and 1.9 
mg/kg [98]. Naloxone produced a 6.4-fold shift to the right 
in the antinociceptive ED50 value of tapentadol while 
yohimbine 1.7-fold only. On the contrary, yohimbine induced 
a 4.7-fold shift in the antihyperalgesic ED50 in comparison to 
the 2.7-fold shift induced by naloxone; ritanserin did not 
induce changes neither on the antinociceptive nor on the 
antihyperalgeisc effect of tapentadol [98].  
 The predominant role of NE reuptake inhibition in NP 
and of µ opioid stimulation in acute pain was suggested [98]. 
A recent research conducted by Meske [99] studied the 
effects of tapentadol administration in sham and SNL rats vs 
morphine and duloxetine. All these drugs showed significant 
and time-related reversal of tactile hypersensitivity. 
Tapentadol (30 mg/kg) was able to significantly increase NE 
levels in the cerebrospinal fluid (CSF) in both sham and SNL 
rats even if the effect was long lasting in SNL only. 
Duloxetine was able to increase NE levels in both groups of 
rats while morphine, at the same doses able to reverse tactile 
hypersensitivity, reduced NE levels in spinal CSF of both 
groups [99] On the other hand, a broad range of preclinical 
and clinical studies on analgesia has demonstrated that 
opioid and α2 AR mechanisms are interdependent. It is 
widely known that α2 AR stimulation enhances the 
antinociceptive effect of µ-opioids, while α2 AR antagonists 
such as yohimbine or idazoxan attenuate morphine analgesia 
in several pharmacological tests. Genetically-altered mice 
lacking NE, showed a significantly attenuation of the 
antinociceptive effect induced by morphine [100]. Moreover, 
early studies demonstrated the increase of NE release into 
the CSF after morphine microinjections into the PAG or 
RVM [101-104]. 
 Summarizing tapentadol effects against NP are imputable 
to increased NE levels and to the synergy between µ and α2 
receptors. 
1.4. An Overview of Compounds Present in the Recent 
Literature 
1.4.1. Tianeptine 
SN
O O
Cl
HN
OH
O
((RS)-7-(3-chloro-6-methyl-6,11-
dihydrodibenzo[c,f][1,2]thiazepin-11-ylamino)
heptanoic acid S,S-dioxide)  
 Tianeptine is a 3-chlorodibenzothiazepine nucleus with 
an aminoheptanoic side chain. Tianeptine is considered an 
atypical antidepressant with some structural similarities to 
TCAs but with distinct neurobiological properties [105]. In a 
recent study, intrathecal administration of tianeptine was 
performed to assess the effect of tianeptine on mechanical 
allodynia in a neuropathic model induced by ligation of L5 
and L6 spinal nerves [106]. Tianepine significantly increased 
the paw withdrawal threshold in a dose-dependent manner 
with a ED50= 102.1 µg and a maximum effect 15-30 min 
after administration; its antinociceptive effect was reversed 
by yohimbine and dihydroergocristine. In the same study an 
extracellular increase of 5-HT and NE concentration in the 
spinal dorsal horn was observed within 15 min after 
tianepine administration (about 15-fold the baseline value).  
1.4.2. A-1262543 
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at concentration up to 10 µM). This compound, tested in the 
SNL model of NP, is able to produce a dose-dependent anti-
allodynic effect, decreasing the hypersensitivity of 42%, 
66% and 84% at the doses of 1, 3 and 10 mg/kg ip 
respectively. In the same study it was demonstrated that the 
anti-allodynic effect is mediated via the ascending 
nociceptive system [107]. 
1.4.3. Beloxepin 
O
CH3
N
H OH
H3C
* *
[(±) cis-1,2,3,4,4a,13b-hexahydro-2,10-
dimethyldibenz[2,3:6,7]oxepino[4,5-c]pyridine-4a(2H)-ol  
 Beloxepin (Org-4428) belongs to the family of 
diphenylossepine [108] and it was studied as antidepressant 
agent at the end of 1990 [109]. It is a selective inhibitor of 
synaptosomal noradrenalin reuptake being about 100-fold 
less affine for other monoamine carriers [110]. The values of 
NE transporter affinity of the raceme (±) and of the pure 
enantiomers, clearly indicate that the (-)-enantiomer binds 
with about 8-fold higher affinity at the transporter with 
respect to (+)-enantiomer (Ki(±) 700 nM, Ki(-) 390 nM and 
Ki(+) 2960 nM) [111]. Although (±) beloxepin is a weak 
inhibitor of NE reuptake, it is active in the treatment of the 
neuropathic pain. It produces a dose-dependent antiallodynic 
effect in L5 SNL rats 16 days post surgery (3, 10 and 30 
mg/kg i.p.). A potent antiallodynic affect was recorded after 
30 mg/kg injection reaching threshold values very similar to 
that of sham-operated rats. Moreover, (±) beloxepin and (-) 
beloxepin are effective in the same model of neuropathic 
pain when administered per os. They produce significant 
antiallodynic effect tested at 60 mg/kg, 60 and 120 minutes 
post drug. Finally, in the same conditions, the (+) enantiomer 
doesn’t show significant antiallodynic effect [110, 111]. 
1.4.4. Conopeptides 
 It is well known the potency and the chemical stability of 
the venom peptides, properties which make these natural 
products a very attractive source for the discovery and the 
development of new drugs [112-114]. At the beginning of 
2000, studies performed on conotoxin, Mr1A, belonging to 
χ-conopeptide family [115, 116], showed its ability to 
produce antinociception after intrathecal administration in 
mice [117] and was found to be a selective and reversible 
inhibitor of neuronal NE transporter [115, 116, 118]. 
Xen2174 is another χ-conopeptide with chemical stability, 
efficacy and safety profile more favorable with respect to 
Mr1A, and it was extensively studied [113]. The intrathecal 
administration of this compound produced dose-dependent 
relief of mechanical allodynia induced in rats by two 
different models of NP, CCI and L5/L6 spinal-nerve injury. 
At the doses able to reverse allodynia, side-effects were mild 
with absence of sedation. The anti-allodinic effect was 
reverted by intrathecal co-administration of yohimbine (100 
nmol), this data confirming the noradrenergic system 
involvement [119]. Brust and co-workers [120] proposed a 
pharmacophoric model for the allosteric binding of Xen2174 
to NE transporter. In this model the interaction between 
Xen2174 and NE transporter is predominantly with 
aminoacids in the first loop, while the second loop interacts 
with a big hydrophobic pocket within the transporter (Fig. 1).  
 
 
 
Fig. (1). Proposed pharmacophore model for the χ-conopeptides 
(from Brust et al.) [120]. 
 
1.4.5. Miscellaneous 
 In the past years the Authors of the present review 
published some articles on antinociceptive agents whose 
effect was demonstrated to be mediated by noradrenergic 
system [121-124]. They report here new data about the most 
interesting compound, 6a [124] (now renamed ET-1), a 
potent and orally active antinociceptive agent acting as α2 
AR agonist [124].  
 
NN
O CH3
H2N
(CH2)3 N N CH3
4-amino-6-methyl-2-(3-(4-(4-methylcyclohexa-1,3-
dien-1-yl)piperazin-1-yl)propyl)-5-vinylpyridazin-
3(2H)-one
ET-1
 
 As shown in Fig. (2), repeated treatment with oxaliplatin, 
an anticancer agent able to induce a dramatic peripheral 
neuropathy [125-127], was able to reduce the licking latency 
of mice placed on a cold surface (Cold plate test) from 21.5± 
1.4 s (vehicle + vehicle) to 10.8±1.7 s (oxaliplatin + vehicle). 
Acute administration of 10 mg kg-1 ET-1 significantly 
increased the pain threshold reaching a peak between 15 and 
30 min after administration and vanishing 45 min later. ET-1 
showed a dose dependent effect, completely reverting 
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oxaliplatin-induced pain at 40 mg kg-1. The pain reliever 
properties of the compound were completely reverted by the 
pretreatment with the α2 AR antagonist yohimbine (3 mg kg-1), 
confirming the α2 AR-mediated pharmacodynamic also in 
NP (Fig. 2).  
 Moreover, the pain reliever ET-1 dosages were able to 
significantly increased NE extracellular levels in rat cerebral 
cortex (Fig. 3).  
 
 
 
Fig. (2). Effect of ET-1 on oxaliplatin-induced neuropathic pain, 
Cold plate test. Mice were daily intraperitoneally treated with 
oxaliplatin 2.4 mg kg-1 for 14 days. On day 14, ET-1 (10, 30 and 40 
mg kg-1) was per os acutely administered. The response to a thermal 
stimulus was evaluated by the Cold plate test measuring the latency 
to pain-related behaviour (lifting or licking of the paw). Control 
animals were treated with vehicles. ^^P<0.01 vs vehicle + vehicle 
treated mice; *P<0.05 and **P<0.01 vs oxaliplatin + vehicle treated 
mice. Each value represents the mean of 10 mice.  
 
 
 
Fig. (3). Effect of ET-1 (10 – 30 mg kg-1 i.p.) on noradrenaline 
extracellular levels from rat cerebral cortex. **P<0.01 vs vehicle.. 
Each value represents the mean of 6 rats.  
 The Pfizer (Wyeth) Group has extensively investigated 
the field of norepinephrine reuptake inhibitors, producing a 
large number of studies [128-134]. Maintaining the 3-amino-
2-hydroxy-1-phenylpropyl fragment as suitable template for 
CNS drug, they selected a series of scaffolds such as aniline 
[128], indole [129] and benzimidazole [130]. Many 
compounds belonging to the series of 1-(indolin-1-yl)-1-
phenyl-3-propan-2-olamines (A) exhibited potent inhibition 
of NE transporter with an IC50 in the nanomolar range and a 
good selectivity toward DA and 5-HT transporter. The most 
interesting compounds also showed favorable drug like 
properties, such as lipophilicity value and molecular weight. 
Compound 9p, a potent NE transporter inhibitor (NE uptake 
inhibition IC50 6.5 nM; NE transporter binding IC50 4.1 nM) 
and very selective (814-fold) over the 5-HT transporter, was 
selected for evaluation in a rat SNL model of NP. Results 
showed that it is able to reverse the mechanical hyperalgesia 
in dose-dependent manner at doses of 10 and 30 mg/kg per 
os [129].  
 
N
OH
H
N
R2
R3
R1
N
OH
H
N
A
F
F
9p
[(1S,2R)-1-(3,5-difluorophenyl)-1-(3,3-
dimethylindolin-1-yl)-
3-(methylamino)propan-2-ol]  
 
 The 7-fluoroanalogue of 9p, WAY-318068 [131, 132] 
was studied for its antidepressant properties and as 
antihyperalgesic agent in pre-clinical model of neuropathies. 
It is a potent and selective inhibitor of NET showing a Ki = 
8.7 nM in a radioligand binding assay and an IC50 = 6.8 nM 
in a functional NE uptake assay. Moreover, microdialysis 
conducted after WAY-318068 administration in rats showed 
a significantly increase of NE but not 5-HT levels in 90 to 
240 min post-dosing range. It is orally bioavailable and a 
significant amount of drug was found in the CNS after oral 
administration. In the NP model induced by SNL, oral 
administration of this compound 3 weeks after surgery 
produced a dose-dependent reduction in mechanical 
hyperalgesia with the maximum efficacy achieved after 5 h 
following the 100 mg/kg dose. In the STZ model of diabetic 
NP, oral administration of WAY-318068 led to an increased 
latency to nociceptive response to thermal stimulation 3 h 
after administration at the doses of 3–30 mg/kg. The good 
pharmacological and pharmacokinetic properties of WAY-
318068, together with its potency and selectivity make this 
compound a good candidate for further development [132]. 
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N
O
F
NH
OH
F
F
(1-[(1S,2R)-1-(3,5-difluorophenyl)-2-hydroxy-3-(methylamino)propyl]-
7-fluoro-3,3-dimethyl-1,3-dihydro-2H-indol-2-one)
WAY-318068
 
 
 The replacement of indole with benzimidazolone let to 
obtain a series of 3-(3-amino-hydroxy-1-phenylpropyl)-1,3-
dihydro-2H-benzimidazol-2-ones derivatives (B) [130]. 
SARs analysis showed the importance of the size of the 
substituent at N-1 on the NE transporter potency: the activity 
is maximum for the terms bearing an ethyl or a propyl group 
at position 1 (IC50 = 13.4-186 nM), whereas it decreases 
when at the same position a smaller (methyl) or a bigger 
group (t-butyl, c-butyl, or c-pentyl) was inserted. Compound 
20 is one of the most interesting terms, (NE transporter 
inhibition IC50 = 7.4 nM, NE transporter binding IC50 = 6.4 
nM, 5-HT transporter 15% inhibition at 1 µM, DA 
transporter 2% inhibition at 10 µM) was selected for further 
investigation in both acute and neuropathic pain. In 
particular, in the model of rat SNL, it significantly and dose-
dependent reversed the mechanical hyperalgesia at 3 and 10 
mg/kg p.o., suggesting its potential use for the treatment of 
NP. 
 
N
N
OH
H
N
R2
X
R3
O
N
N
OH
H
N
O
F
Y
20
B
(1-ethyl-3-((1S,2R)-1-(3-fluorophenyl)-2-
hydroxy-3-(methylamino)propyl)-1H-
benzo[d]imidazol-2(3H)-one)  
 
 The same research group successively focused their 
attention on the benzothiadiazole scaffold [133, 134], 
synthesizing a series of derivatives C, evaluating structure-
activity relationships and finally identifying two lead 
compounds, S-17b (WYE-103231, 4-[3-(2-fluorophenyl)-
2,2-dioxo-2,3-dihydro-2λ6-benzo[1,2,5]thiadiazol-1-yl]-1-
methylamino-butan-2-ol) [133] and 10b (WYE-114152,  
1-(2-fluorophenyl)-3-(2-morpholin-2-yl-ethyl)-1,3-dihydro-
benzo[1,2,5]thiadiazole 2,2-dioxide) [134] with the best 
balance among potency as inhibitor of the NE transporter, 
selectivity over both 5-HT and DA transporter and 
pharmacokinetic profile. Compound S-17b (NE transporter 
inhibition IC50 = 1 nM, NE transporter binding IC50 = 6 nM) 
showed high to moderate clearance, high volume of 
distribution, a long half-life (3.2-6.3 h, depending on the 
species), a good brain penetration and finally a 
bioavailability from 41% to 100% [133]. S-17b, tested on 
SNL model of NP, was found able to significantly reduce in 
a dose dependent manner, the mechanical hyperalgesia at 5, 
7, 10 and 30 mg/kg. The second one lead, compound 10b 
(NE transporter inhibition IC50=15 nM, NE transporter 
binding IC50=5 nM) [134] is an analogue of S-17b in which 
the NH and OH groups of the lateral chain have been 
cyclized into the morpholine ring and it was selected for its 
pharmacokinetic parameters, such as clearance, good brain 
penetration and moderate half-life. Moreover, microdialysis 
studies in rats demonstrated that administration of 10b at 30 
mg/kg po increased till 390% the levels of NE in the medial 
prefrontal cortex without effect on 5-HT levels. Finally, 10b 
reduced hyperalgesia in SNL model of NP at the doses of 3, 
10 and 30 mg/kg po [134]. This compound is a good 
candidate for further development. 
 
N
S
N
Ar
R
O
O
C
N
S
N O
O
F
NH
O
(WYE-114152)
N
S
N O
O
F
HN
HO
(WYE-103231)
4-[3-(2-fluorophenyl)-2,2-dioxo-2,3-
dihydro-2!6-benzo[1,2,5]thiadiazol-
1-yl]-1-methylamino-butan-2-ol)
1-(2-fluorophenyl)-3-(2-
morpholin-2-yl-ethyl)-1,3-dihydro-
benzo[1,2,5]thiadiazole 2,2-
dioxide)  
 
 A research performed by Chen and coworkers [135] on 
analogues of Milnacipran afforded potent NE/5-HT 
transporter inhibitors, whose pharmacological and 
pharmacokinetic profile has been widely investigated. The 
most interesting compound of the series, 5c, exhibited IC50 = 
2.3 and 32 nM at NE and 5-HT transporters respectively, 
more than 10-fold better than Milnacipran. Moreover, it was 
tested in a panel of binding assay of about 70 different 
receptors, enzyme, transporter and ion channels at 10 mM, 
but no significant activity was recorded. Studies of 
α 2 Adrenoceptor: A Target for Neuropathic Pain Treatment Mini-Reviews in Medicinal Chemistry, 2016, Vol. 16, No. 0     9 
metabolism indicated that 5c is less stable than Milnacipran. 
The pharmacokinetic parameters were determined in 
different species and it was seen that 5c had the highest oral 
bioavailability in mice (92%), followed by dog (78%) and 
monkey (34%). Also for 5c was demonstrated the correlation 
between NE and 5-HT transporter inhibition and its ability to 
reverse mechanical hyperalgesia induced by SNL. Tested at 
the dose of 30 mg/kg it produced an excellent 
antihyperalgesic effect (about 60% reversal) comparable 
with that of Milnacipran tested at higher doses (60 and 100 
mg/kg). 
 
S
N
O
NH2
5c
((1R,2R)-N,N-diallyl-2-(aminomethyl)-1-(thiophene-2-
yl)cyclopropanecarboxamide)  
 
 Among the drugs that act specifically on multiple targets, 
(classified as Designed Multiple Ligands, DMLs) other than 
the above reported, a new class has been discovered by 
Mladenova and coworkers [136]. Taking into account that 
both NE and nitric oxide are involved in pain, and starting 
from the similarities between the NE transporter and the 
nitric oxide synthase (NOS) pharmacophore models, they 
designed and synthesized a series of 3,5-disubstituted indole 
derivatives with dual action, as human neuronal NOS and 
NE reuptake inhibitors. They found that the cis analogues 
showed better selectivity for neuronal NOS (nNOS) over the 
endothelial one (eNOS), while the differences of 
conformation were not important for the NE transporter 
activity. Cis-(+)-37 was selected as lead compound, 
exhibiting excellent potency for nNOS (IC50 = 0.56 µM) and 
NE transporter (IC50 = 1.0 µM) with a good selectivity over 
eNOS and inducible NOS (iNOS). Compound cis-(+)-37 was 
evaluated for the contractile response on human resistance 
arteries (inhibition of acetylcholine-mediated relaxation), in 
order to find cardiovascular effects associated with eNOS 
inhibition, but no effect was recorded and this data is in 
agreement with the low inhibitory potency in human eNOS 
(IC50 = 49.3 µM). In the SNL model of NP, the i.p. 
administration of cis-(+)-37 (30 mg/kg) led to a reversion of 
allodynia and thermal hyperalgesia and the maximum effect 
was observed at 30 min. (90% allodynia and 96% thermal 
hyperalgesia). These results allowed the Authors to assert 
that cis-(+)-37 shows a dual action activity, since their 
previously reported pure nNOS compounds reverted only the 
thermal hyperalgesia [137]. This compound, further 
investigated in a panel of different receptors, ion channels 
and transporter at 10 µM, showed a good profile and at the 
present is under evaluation in NP. 
N
H
H
N
NH
S
H
N
cis-(+)-37
(N-(3-(3-(methylamino)cyclohexyl)-1H-indol-5-yl)thiophene-2-
carboxamide)  
 
 Finally, it is interesting to mention Agmatine, an 
endogenous substance synthesized from L-arginine by the 
enzyme arginine decarboxilase [138]. It was identified in 
mammalian and it is widely distributed in a variety of tissues 
including the brain [139, 140] and it acts as antagonist of 
glutamate receptors and as inhibitor of NOS but also binds 
with high affinity the α2 AR [141, 142]. Fairbanks et al. 
[143] first demonstrated that i.t. administration of agmatine 
relieved carrageenan-induced mechanical and muscle 
inflammatory hyperalgesia in mice; afterwards it was 
demonstrated that agmatine is active (10-400 mg/kg) on NP 
in a rat model [144] and that this effect involves the 
reduction of NO levels as well as noradrenergic activity in 
the brain. These results were also confirmed by Paszcuk et 
al. [145] which observed that agmatine (30 mg/kg i.p.) 
significantly reduced the mechanical hypernociception 
caused by partial sciatic nerve ligation in mice during 6 h, 
with inhibition of 81%. 
 
H2N
N NH2
NH2
2-(4-aminobutyl)guanidine  
CONCLUSIONS 
 Chronic pain management is a challenge entrusted to a 
limited number of effective therapeutic options [146] and 
novel pharmacological targets [114, 147, 148]. α2 AR 
emerges as a key player in the pathological nervous network 
underlying neuropathic pain. Direct and indirect stimulation 
offers an interesting approach to relieve pain and favor 
homeostasis. New potent α2 AR modulators are currently 
being evaluated. 
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